Biote (BTMD) announced that several members of its board of directors, along with CEO Bret Christensen, have made open market purchases of ...

The board is very confident in Bret’s ability to make decisive and material changes at Biote to grow our business. With his deep expertise spanning the diagnostic, therapeutic and medical device ...

Biote Corp. (BTMD) came out with quarterly earnings of $0.10 per share, beating the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.14 per share a year ago. These figures ...

Investment analysts at B. Riley issued their Q1 2025 earnings per share estimates for shares of biote in a research note ...

These updates follow the latest evidence-based medical literature and feature proprietary dosing algorithms that are unique in the marketplace. With these new algorithms, Biote-certified ...

personalized hormone optimization and therapeutic wellness solutions delivered by Biote-certified medical providers. Biote trains practitioners to identify and treat early indicators of aging ...

biote Corp. (NASDAQ:BTMD – Free Report) – B. Riley issued their Q3 2025 earnings per share (EPS) estimates for biote in a research note issued to investors on Thursday, March 13th. B.

biote Corp. , which belongs to the Zacks Medical - Products industry, posted revenues of $49.83 million for the quarter ended December 2024, missing the Zacks Consensus Estimate by 2.85%.

IRVING, Texas, March 18, 2025--biote Corp. (NASDAQ: BTMD) ("Biote" or the "Company") a leading solutions provider in preventive health care through the delivery of personalized hormone optimization ...

Good day and welcome to the Biote fourth quarter 2024 earnings conference call. (Operator Instructions) Please note that this event is being recorded. I would now like to turn the conference over ...